Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Radiat Oncol. 2013 Jan 2;8:2. doi: 10.1186/1748-717X-8-2.
To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL).
Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the orbita (n = 8), breast (n = 1) and one case of marginal zone lymphoma of the skin (n = 1). The median radiotherapy dose was 40 Gy (5 to 45 Gy).
The median follow-up time was 103 months. The 5-year overall survival and event-free survival rates were 85 ± 7% and 71 ± 9%, respectively. There was no infield recurrence. Recurrence occurred outside of the radiation field in six patients. The relapses were treated with salvage RT and had excellent local control (100%) at five years after salvage RT.
Localized extranodal MZL have an excellent prognosis following moderate-dose RT. RT is also an effective salvage therapy in cases of localized recurrence. Further clinical studies should evaluate the optimal dose for MZL.
评估放疗（RT）治疗早期结外边缘区淋巴瘤（MZL）的疗效。
回顾性分析了 22 例 I 期和 8 例 II 期接受 RT 治疗的 MZL 患者。主要肿瘤部位包括眼眶（n=12）、胃（n=8）、头颈部（n=8）、乳房（n=1）和皮肤边缘区淋巴瘤（n=1）。中位放疗剂量为 40Gy（5-45Gy）。
中位随访时间为 103 个月。5 年总生存率和无事件生存率分别为 85±7%和 71±9%。无场内复发。6 例患者肿瘤在放疗野外复发。复发患者接受挽救性 RT 治疗，挽救性 RT 治疗后 5 年局部控制率为 100%。
局限性结外 MZL 接受中等剂量 RT 治疗后预后良好。RT 也是局部复发的有效挽救治疗方法。应进一步开展临床研究以评估 MZL 的最佳剂量。
